All News

In this "Coding Q&A," the Painters also answer a question regarding coding for sling and cystocele repair with mesh repair.

This article provides a practical explanation of MACRA and the Quality Payment Program and what they mean for practicing urologists.

The new draft recommendation on PSA screening from the U.S. Preventive Services Task Force (USPSTF), which improves the previous D rating for all men to a C rating for those ages 55 to 69 years, has been met with guarded approval by three of the key national organizations representing urologists.

Participants in an outreach event for prostate cancer screening preferred education about prostate cancer prior to undergoing screening, and thought the use of an informed decision-making model was beneficial, researchers reported at the Genitourinary Cancers Symposium in Orlando, FL.

In this article, urologists Scott E. Eggener, MD, and Stacy Loeb, MD, MSc, discuss the current applications for prostate cancer biomarkers and MRI, their impact on clinical practice, and future developments.

This article discusses the current status and potential future developments in immunotherapy for genitourinary malignancies with insights from urologic oncology specialists Hyung L. Kim, MD, and Daniel P. Petrylak, MD.

The role of protein- and cell-based urinary biomarkers for bladder cancer detection and surveillance is controversial, and in 2017 these assays have yet to come into widespread use among urologists. Their uptake is expected to increase, however, considering that the AUA/Society of Urologic Oncology “Guideline on Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer” that was released in 2016 identifies situations for using urinary biomarkers, according to Badrinath R. Konety, MD.

This article highlights the key points of two urologic cancer guidelines (which provide evidence-based guidance) and two consensus statements (which provide consensus recommendations by a multidisciplinary panel of experts) that have been published in the past year.

While no resource is perfect, it is worthwhile to familiarize yourself with some contemporary methodology and predictive tools to help determine life expectancy in localized prostate cancer patients.

“The data from our study show that combination therapy [for metastatic renal cell carcinoma] may offer a much higher response rate with manageable side effects,” says study author Jianjun Gao, MD, PhD.

A recent study found that decreased pelvic floor strength after childbirth is 2.5 times more likely to affect women over age 25 years than younger women.

“The immune system may be an under-recognized contributor to the tumor response to chemotherapy,” said researcher Philip H. Abbosh, MD, PhD.

A recent study found that compared to white light cystoscopy, fluorescent cystoscopy was linked to a 41% decreased risk of bladder cancer recurrence at less than 3 months.

Urology Times reached out to three urologists (selected randomly) and asked them each the following question: Do you prescribe MET for stone patients?

Urologist Henry Rosevear, MD, thinks it may be time to bring patients into the prior authorization process.

Two recent JAMA studies confirm a higher rate of sexual and urinary side effects with radical prostatectomy compared with radiation therapy and surveillance.

The update provides evidence-based recommendations for different patient risk groups and specifies the most effective forms of the treatment for patients with prostate cancer.

In these videos, expert surgeons demonstrate robot-assisted penile inversion vaginoplasty, single-stage metoidioplasty, and simple orchiectomy for transgender patients.

Other pipeline developments include efficacy results for a bladder and prostate cancer drug, an infertility tool to predict sperm quality, the initiation of an immunotherapy combination for mUC, and more.

Among urologists, prior authorization ranks as their second most pressing concern, according to Urology Times’ 2016 State of the Specialty survey. The same survey showed the problem is getting worse, with 86% of respondents reporting that prior authorization demands are increasing.

Two topics of particular relevance at the 2017 Joint Advocacy Conference were IPAB repeal and medical liability reform, both of which have legislative initiatives currently gaining momentum in Congress.

The noninvasive molecular test for detecting recurrent urothelial carcinoma also demonstrates high negative predictive value in a prospective study.

Tom Wooldridge, PsyD, addresses misinformation regarding eating disorders in men.

In the arena of focal therapy for prostate cancer, standardization of management will be a key component of quality data going forward, says Scott Eggener, MD.

Urology Times reached out to four urologists (selected randomly) and asked them each the following question: How concerned are you about radiation exposure?

A 5-year-old girl is evaluated for recurrent urinary tract infections and lower abdomen pain. A kidney, ureter, and bladder x-ray and computed tomography are obtained.

Phase III study results suggest that a hydrogel spacer developed to separate the rectum and prostate during radiotherapy for prostate cancer works to maintain bowel and urinary quality of life and reduces late rectal toxicity by 78% at 3 years post radiotherapy.